drugset / Trial / NCT02421289

Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients

NCT02421289

Phase 1 Unknown 190 enrolled Mahidol University
RandomizedParallel-groupDouble-blindTreatment

Summary

Genetic polymorphisms of cytochrome P450 2B6 (CYP2B6) are associated with lower rate of EFV metabolism and lead to high exposure, as well as a higher risk of neuropsychiatric adverse event especially homozygous variant CYP2B6 \*6/\*6. This trial was designed to compare the proportion of patients who had undetectable HIV RNA at 24 weeks after ART initiation between patient who did CYP 2B6 guided EFV dose and who did not.

Timeline

Start
2013-04
Primary completion
2014-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavirenz Other / unclassified 400 mg
Subject Efavirenz Other / unclassified 600 mg